NASDAQ:ORTX Orchard Therapeutics (ORTX) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free ORTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.70▼$16.7050-Day Range$16.40▼$16.7052-Week Range$4.24▼$16.72VolumeN/AAverage Volume157,287 shsMarket Capitalization$380.09 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Orchard Therapeutics alerts: Email Address Orchard Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside49.7% Upside$25.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.25) to ($4.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.51 out of 5 starsMedical Sector871st out of 914 stocksBiotechnology Industry6th out of 10 stocks 3.2 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOrchard Therapeutics has received no research coverage in the past 90 days.Read more about Orchard Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ORTX. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 13 news articles for Orchard Therapeutics this week, compared to 9 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.90% of the stock of Orchard Therapeutics is held by institutions.Read more about Orchard Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($5.25) to ($4.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -17.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Orchard Therapeutics Stock (NASDAQ:ORTX)Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..Read More Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. ORTX Stock News HeadlinesMay 19 at 7:45 PM | msn.comION Orchard dives into gamification amidst experiential retail demandMay 19 at 9:42 AM | msn.comMan fatally shot Sunday morning in Plum Orchard area, NOPD saysMay 18 at 6:45 PM | mirror.co.ukMeghan Markle set to embark on huge PR campaign to promote American Riviera OrchardMay 18 at 1:21 AM | msn.comOld Orchard Beach Pier opens for the seasonMay 17 at 3:18 PM | msn.comOrchard Mesa Baptist Church holds RV raffleMay 17 at 3:18 PM | bizjournals.comOrchard Park home sells for $1.1 millionMay 17 at 12:28 AM | msn.comOpening date set for New York Beer Project's Orchard Park locationMay 16 at 7:28 PM | msn.comZara Opens New, Expanded Flagship Store At Westfield Old Orchard MallMay 16 at 7:28 PM | msn.comMassive Zara opens inside newly renovated Lord & Taylor building at Westfield Old OrchardMay 16 at 9:23 AM | msn.comLuxury hotel The Singapore Edition just officially launched – and looks poised to rise above competitors along Orchard Road: we attended the buzzy opening party with Donnie ...May 16 at 9:23 AM | yahoo.comNew York Beer Project Beer Lodge in Orchard Park official grand opening set for June 14May 15, 2024 | msn.comReport: Bills set for Week 11 rematch with Chiefs in Orchard ParkMay 14, 2024 | msn.comVehicle causes damage to headstones at Indian Orchard cemeteryMay 12, 2024 | theguardian.comThe week in theatre: The Cherry Orchard; Minority Report; Laughing Boy – reviewMay 12, 2024 | msn.comMan wanted for Aggravated Assault on Peach Orchard RoadMay 11, 2024 | msn.com'I'm just in disbelief': Port Orchard family calling for change after their pet pigs were wrongly killedMay 10, 2024 | msn.comPort Orchard man arrested in connection with alleged rapeMay 10, 2024 | msn.comPort Orchard man charged with rape, providing alcohol to 18-year-oldMay 10, 2024 | msn.com2 popular Westfield Old Orchard stores will soon move locations; opening timelines revealedMay 10, 2024 | msn.comPet pigs in Port Orchard wrongly killed, owners call for change and accountabilityMay 9, 2024 | msn.comFly Creek Cider Mill & Orchard set to open for the seasonMay 7, 2024 | msn.comCommunications agency Orchard being acquired by its employeesMay 7, 2024 | globenewswire.comOrchard Therapeutics Announces Multiple Presentations at ASGCT 2024May 7, 2024 | sg.style.yahoo.comConrad Singapore Orchard hotel review: A foodie hotel destinationMay 4, 2024 | nytimes.com‘The Cherry Orchard’ Review: Chekhov in the Fun ZoneSee More Headlines Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$34.00 Low Stock Price Target$16.00 Potential Upside/Downside+49.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,660,000.00 Net Margins-333.90% Pretax Margin-334.54% Return on Equity-74.94% Return on Assets-33.51% Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio2.98 Sales & Book Value Annual Sales$22.66 million Price / Sales16.77 Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book2.16Miscellaneous Outstanding Shares22,760,000Free Float22,099,000Market Cap$380.09 million OptionableOptionable Beta0.55 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Hubert Baburaj Gaspar M.D. (Age 61)Ph.D., CEO, Member of Scientific Advisory Board & Executive Director Comp: $901.42kMr. Frank Edward Thomas (Age 55)President & COO Comp: $763.95kDr. Nicoletta Loggia Ph.D.R.Ph., Chief Technical OfficerDr. Fulvio Mavilio Ph.D.Chief Scientific OfficerMs. Renee T. LeckHead of Investor RelationsBenjamin NavonDirector of Corporate CommunicationsMr. John CerioChief Human Resource OfficerMr. Robin KenselaarSenior VP & GM of EMEA Commercial OperationsMr. Braden ParkerChief Commercial OfficerDr. Leslie Meltzer Ph.D.Chief Medical OfficerMore ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKAlto NeuroscienceNYSE:ANROAurora CannabisNASDAQ:ACBCerusNASDAQ:CERSOrganogenesisNASDAQ:ORGOView All Competitors ORTX Stock Analysis - Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares. View ORTX analyst ratings or view top-rated stocks. What is Orchard Therapeutics' stock price target for 2024? 3 brokers have issued twelve-month price targets for Orchard Therapeutics' stock. Their ORTX share price targets range from $16.00 to $34.00. On average, they expect the company's share price to reach $25.00 in the next year. This suggests a possible upside of 49.7% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to the consensus estimate of $6.48 million. Orchard Therapeutics had a negative net margin of 333.90% and a negative trailing twelve-month return on equity of 74.94%. When did Orchard Therapeutics' stock split? Orchard Therapeutics's stock reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? Orchard Therapeutics (ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:ORTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.